Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Metastasis02:30

Metastasis

5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
MicroRNAs01:22

MicroRNAs

21.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of the COVID-19 Pandemic on Treatment Strategies for Secondary Prevention of Hip Fragility Fractures.

The Israel Medical Association journal : IMAJ·2026
Same author

Wounding-induced redirection of sugar transport fuels tissue repair.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Machine-learning prediction of affinity and epistasis in the bovine pancreatic trypsin inhibitor-chymotrypsin complex.

Protein science : a publication of the Protein Society·2026
Same author

Predictors of antidepressant prescribing in schizophrenia: A retrospective analysis.

Schizophrenia research·2026
Same author

Beyond black-box AI: Comparing ChatGPT-4 interpretability and accuracy to CNNs in melanocytic lesions diagnosis.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Another prospective study on the safety of ondansetron for nausea and vomiting of pregnancy: addressing ongoing concerns.

Frontiers in pharmacology·2026
Same journal

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma.

Molecular oncology·2026
Same journal

From tumor-centric to ecosystem-based hypotheses in brain tumor research and care: Proceedings from The second Brain Tumor Meeting by the Sea organized by Julie Gavard and Eric Chevet, held in St Malo (France), 23-25 March 2026.

Molecular oncology·2026
Same journal

Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation.

Molecular oncology·2026
Same journal

In vitro and in silico modelling of ROS1-positive non-small cell lung cancer reveals fusion-dependent tyrosine kinase inhibitor responses.

Molecular oncology·2026
Same journal

The role of miR-335-5p in the redifferentiation of BRAF p.V600E thyroid cancers.

Molecular oncology·2026
Same journal

EXPRESSION OF CONCERN: A Newly Identified 45-kDa JAK2 Variant with an Altered Kinase Domain Structure Represents a Novel Mode of JAK2 Kinase Inhibitor Resistance.

Molecular oncology·2026
See all related articles

Related Experiment Video

Updated: Jul 18, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.2K

Serine protease inhibitors decrease metastasis in prostate, breast, and ovarian cancers.

Amiram Sananes1, Itay Cohen1, Irit Allon2

  • 1Avram and Stella Goldstein-Goren Department of Biotechnology Engineering and the National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Molecular Oncology
|August 23, 2023
PubMed
Summary
This summary is machine-generated.

New therapies targeting mesotrypsin and kallikrein 6 (KLK6) proteases show promise for advanced prostate, breast, and ovarian cancers. These novel agents, based on amyloid β-protein precursor Kunitz protease inhibitor domain (APPI) mutants, effectively target tumors and inhibit metastasis.

Keywords:
cancer imagingkallikreinsmetastasisprotease inhibitorsserine proteases

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.2K

Related Experiment Videos

Last Updated: Jul 18, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.2K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.2K

Area of Science:

  • Oncology
  • Biochemistry
  • Drug Discovery

Background:

  • Current cancer therapies primarily target primary tumors, neglecting the metastatic process.
  • Metastasis in prostate, breast, and ovarian cancers is linked to increased activity of mesotrypsin and kallikrein 6 (KLK6).
  • Mesotrypsin and KLK6 are identified as crucial targets for anti-metastatic interventions.

Purpose of the Study:

  • To develop novel therapeutic agents targeting mesotrypsin and KLK6 for advanced metastatic cancers.
  • To evaluate the efficacy and properties of APPI-based mutants as anti-metastatic therapies.
  • To explore the potential of these agents for cancer imaging.

Main Methods:

  • Development of engineered mutants of the human amyloid β-protein precursor Kunitz protease inhibitor domain (APPI).
  • Designation of APPI-3M for prostate and breast cancers, and APPI-4M for ovarian cancer.
  • Preclinical testing in orthotopic models to assess tumor accumulation, therapeutic efficacy, and pharmacokinetic properties.

Main Results:

  • APPI-3M and APPI-4M mutants showed significant accumulation within tumors.
  • Demonstrated therapeutic efficacy in preclinical models of advanced metastatic cancers.
  • Exhibited long in vivo retention times, high affinity, and favorable pharmacokinetics.

Conclusions:

  • Engineered APPI mutants represent a promising novel therapy for metastatic prostate, breast, and ovarian cancers.
  • These agents possess characteristics suitable for both therapeutic intervention and diagnostic imaging.
  • The developed therapies have a good safety profile and are manufacturable at scale.